Arcturus Therapeutics Holdings (ARCT) Receivables (2018 - 2026)

Arcturus Therapeutics Holdings has reported Receivables for 9 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 90.78% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (down 90.78% YoY), and the FY2025 full-year result was $11.1 million, up 40.01% from the prior year.
• Receivables for Q1 2026 stood at $2.7 million, down from $11.1 million in the prior quarter.
• The five-year high for Receivables was $185.0 million in Q1 2023, with the low at $2.7 million in Q1 2026.
• Historically, Receivables has averaged $36.3 million across 5 years, with a median of $15.9 million in 2025.
• Annual changes were most pronounced in 2023 — Receivables jumped 2405.64% — and 2026, when it sank 90.78%.
• Arcturus Therapeutics Holdings' Receivables stood at $5.5 million in 2022, then surged by 1060.06% to $64.1 million in 2023, then plunged by 87.61% to $7.9 million in 2024, then soared by 40.01% to $11.1 million in 2025, then plunged by 75.86% to $2.7 million in 2026.
• The last three Receivables figures came in at $2.7 million (Q1 2026), $11.1 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.